Jefferies Maintains a 'Buy' on Express Scripts (ESRX); Incurs High Q4 Expenses As Its Preps For MHS Integration

Jefferies maintains a 'Buy' on Express Scripts (NASDAQ: ESRX) price target raised from $55 to $60.

Analyst, Arthur I. Henderson, said, "ESRX's Q4 miss is irrelevant as the stock will continue to trade on the prospects of the company's pending Medco (NYSE: MHS) acquisition. ESRX's Q4 miss resulted from higher expenses incurred to prepare for its upcoming integration of Medco and to avoid Walgreen-induced (NYSE: WAG) customer disruptions. Given our believe there is a high probability that this merger closes by the end of 1H without any material FTC concerns, we are raising our PT to $60."

For an analyst ratings summary and ratings history on Express Scripts click here. For more ratings news on Express Scripts click here.

Shares of Express Scripts closed at $51.63 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• DA Davidson Starts Comfort Systems USA (FIX) at Buy
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand